Overview

A Phase 1 Study to Assess the Effect of Severe Renal Impairment on the Pharmacokinetics, as Well as Safety/Tolerability, of Ranolazine

Status:
Terminated

Trial end date:
2012-08-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the effect of severe renal impairment on the steady-state PK, as well as safety and tolerability, of ranolazine, compared to subjects with normal renal function.

Phase:

Phase 1

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Ranolazine